{
    "nctId": "NCT02670668",
    "briefTitle": "Mutation of BRCA1/2 and Other Potential Genes in Triple-negative Breast Cancer",
    "officialTitle": "Single Centre\uff0cExploratory\uff0cParallel and Retrospective Study to Analysis the Mutation and Expression of BRCA1/2 and Other Potential Genes in Triple-negative Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "BASIC_SCIENCE",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Gene mutation prevalence of tBRCA1/2, HRR, or other chemo-response related genes in TNBC patients between pCR and SD/PD, which achieved after NAC",
    "eligibilityCriteria": "Inclusion Criteria:\n\nPatients receiving neoadjuvant chemotherapy with paclitaxel and carboplation are enrolled in this study.\n\n* (1) histologically confirmed mainly invasive breast carcinoma\n* (2) a unilateral and non-inflammatory tumors\n* (3) status of ER, PR and HER-2 are available and negative\n* (4) The participants are required to have clinical stage II or III breast cancer with a clinical or radiographically measurable residual tumor after core biopsy.\n* (5)patients had pathological evaluation after NAC\n* (6) the pathologic tissues are available for immunohistochemistry and next generation sequencing\n\nExclusion Criteria:\n\n* (1) carcinoma in situ\n* (2) received less than 4 cycles neoadjuvant chemotherapy",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}